Roche’s First-in-Human Trial Marks Milestone for Malaysia’s Clinical Research

Roche Pharmaceuticals, one of the world’s largest pharmaceutical companies, has officially designated Sarawak General Hospital as the site for a First-in-Human (FIH) clinical trial in Malaysia.

Read More News

This announcement was made during CRM’s Clinical Research Excellence in Early Phase and People Development event, which was inaugurated by the Minister of Health, Datuk Seri Dr Dzulkefly Ahmad. Following the announcement, Malaysia will be the seventh country included for this study and the first within the Asia Pacific region, joining along other global sites located in Europe and South Africa.

Human Trial

“Malaysia’s clinical trial ecosystem has developed rapidly with over 2300 clinical research conducted since 2012. CRM through its P1RP initiative have overseen the development of the country’s early phase ecosystem, to enable safe and regulated conduct of early phase research especially FIH trials.

“Following the completion of P1RP in 2021, Malaysia has conducted one FIH and two First-in-Patient studies, with Roche’s study being the first FIH in Malaysia under a rheumatology indication,” said Datuk Seri Dr Dzulkefly during his speech.